Top Markets
#1 Black Phoenix Black Phoenix +356.02%
#2 Glidr Glidr +84.34%
#3 Gold Park Gold Park +55.09%
#4 Akedo Akedo +49.04%
#5 Acurast Acurast +34.81%
#6 FGRS (Figure Tokenized Stock) FGRS (Figure Tokenized Stock) +28.91%
#7 BasedHype BasedHype +25.95%
#8 Avantis Avantis +23.73%
#9 Cryptopia Cryptopia +21.54%
#10 Quantum Resistant Ledger Quantum Resistant Ledger +16.89%
Coin of the day
Black Phoenix Black Phoenix
Settings
Language
ENGLISH
Currency
USD
Theme
GENinCode plc GENinCode plc

GENinCode plc

GENI
Rank in Stocks #41218
GENinCode Plc specializes in the creation and commercialization of advanced... GENinCode Plc specializes in the creation and commercialization of advanced genetic tests designed to forecast potential health risks based on an individual's DNA. Operating in both the United Kingdom and internationally, their predictive technology empowers individuals and medical professionals alike with proactive health management and targeted intervention strategies. The company's sophisticated molecular diagnostics leverage a combination of clinical algorithms and artificial intelligence to deliver precise patient risk assessments, thereby anticipating the onset of various diseases. Among their specialized tests are: Cardio inCode: A patented genetic assay designed to guide individuals in cardiovascular prevention. Lipid inCode: A genetic diagnostic tool that analyzes seven specific genes associated with familial hypercholesterolemia. SUDD inCode: A genetic test to identify the underlying causes of sudden cardiac death and inherited heart conditions. Thrombo inCode: This test assesses 12 genetic variants linked to hereditary thrombophilia and the general risk of thrombosis (blood clots). Thrombo inCode Reproductive Health: Offering crucial insights into thrombophilia risks particularly relevant to prospective pregnancies. Established in 2018, GENinCode Plc maintains its headquarters in Oxford, United Kingdom.
Share Price
$0.01224631
Market Cap
$34.25K
Change (1 day)
0.00%
Change (1 year)
-39.87%
Country
GB
Trade GENinCode plc (GENI)

Category

Healthcare
Revenue for GENinCode plc (GENI)
Revenue in Aug 2026 TTM: 0
According to GENinCode plc latest financial reports the company's current revenue (TTM) is 0. In 2026 the company made a revenue of 0 equal to the revenue in the year 2026 that was 0. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Revenue history for GENinCode plc from 2026 to 2026
Revenue at the end of each year
Year Revenue Change
Not enough data for the provided dates.
Revenue for similar companies or competitors
Company Revenue Revenue Difference Country
Thermo Fisher Scientific Inc. Thermo Fisher Scientific Inc.
Thermo Fisher Scientific Inc.
TMO.US
 $46.34B -
US
Danaher Corporation Danaher Corporation
Danaher Corporation
DHR.US
 $25.11B -
US
WuXi AppTec Co., Ltd. WuXi AppTec Co., Ltd.
WuXi AppTec Co., Ltd.
603259.SS
 - -
CN
Natera, Inc. Natera, Inc.
Natera, Inc.
NTRA.US
 $2.71B -
US
IDEXX Laboratories, Inc. IDEXX Laboratories, Inc.
IDEXX Laboratories, Inc.
IDXX.US
 $4.55B -
US